PAR-25-318: Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2025.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on July 16, 2026.
From the official notice on Grants.gov, last changed June 18, 2026. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR21
- Clinical trialsOptional
- R21, Exploratory/Developmental Research Grant. Early, exploratory ideas that may not have preliminary data yet, usually for up to two years. Other open R21 notices.
Application due dates, page limits and budget limits are set in the notice. Read PAR-25-318 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-23-106 | February 14, 2023 | Closed January 7, 2025 | Closed |
Key dates
| Posted | January 8, 2025 |
|---|---|
| Deadline | July 16, 2026 |
| Archived by Grants.gov | August 15, 2026 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the program's money (77% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Notice of Funding Opportunity (NOFO) is to stimulate HIV/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications Disorders (NIDCD). Applications should address high priority HIV/AIDS research outlined by the NIH Office of AIDS Research (OAR) (https://www.oar.nih.gov/hiv-policy-and-research/research-priorities) in the areas of hearing, balance, taste, smell, voice, speech, and language. For applications proposing a clinical trial, only low risk clinical trials will be supported.
Who has won Research Related to Deafness and Communication Disorders grants before
From fiscal 2021 to 2025, Research Related to Deafness and Communication Disorders (93.173) awarded $2.1 billion across 2,231 grant awards, an average of $925,005 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Johns Hopkins University | Maryland | 73 | $82.4 million |
| Massachusetts Eye and Ear Infirmary | Massachusetts | 41 | $78.9 million |
| The University of Iowa | Iowa | 28 | $53.4 million |
| The Leland Stanford Junior University | California | 39 | $46.2 million |
| University of Wisconsin System | Wisconsin | 56 | $45.0 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-25-318 still open?
No. It closed on July 16, 2026.
Who can apply for Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)?
Closed July 16, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has won Research Related to Deafness and Communication Disorders grants before?
The largest recipients over five fiscal years were The Johns Hopkins University, Massachusetts Eye and Ear Infirmary, The University of Iowa. The program made 2,231 awards worth $2.1 billion in that time.
Similar open grants
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
- Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)
- Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)